{"id":10121,"date":"2004-02-03T10:35:09","date_gmt":"2004-02-03T10:35:09","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=10121"},"modified":"2014-05-22T19:28:08","modified_gmt":"2014-05-22T19:28:08","slug":"uk-named-patient-access-to-tipranavir","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/10121","title":{"rendered":"UK named-patient access to tipranavir"},"content":{"rendered":"<p><strong>The named-patient access to tipranavir that started in Autumn 2003 is still continuing. Entry criteria for this limited programme include:<\/strong><\/p>\n<ul>\n<li>Require tipranavir to construct a viable combination of anti-retroviral agents for therapy based on current treatment guidelines and the patient\u2019s previous anti-retroviral history.<\/li>\n<li>18 years of age or over, or is &gt;\/=13 years of age, with a total body weight &gt;\/= 50kg.<\/li>\n<li>CD4+ count less than 50 cells\/mm3<\/li>\n<li>HIV RNA greater than 10,000 copies\/ml<\/li>\n<\/ul>\n<p>Patients taking or intending to take additional protease inhibitors with tipranavir and ritonavir are currently not eligible for named patient supply.<\/p>\n<p>Clinicians should contact Sarah Jones in the medical division of Boehringer Ingelheim on 01344 742539 or 07776 483808 for further information regarding the programme.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The named-patient access to tipranavir that started in Autumn 2003 is still continuing. Entry criteria for this limited programme include: Require tipranavir to construct a viable combination of anti-retroviral agents for therapy based on current treatment guidelines and the patient\u2019s &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-10121","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/10121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=10121"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/10121\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=10121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=10121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=10121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}